ITI-333 is under clinical development by Intra-Cellular Therapies and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ITI-333’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ITI-333 is under development for the treatment of opioid use disorder, pain and mood disorders (depression and anxiety). It is administered through oral route as a solution. The drug candidate acts by targeting D1A dopamine receptor, Mu type opioid receptor, serotonin 5-HT2A receptor. It is developed based on CNSProfile platform.
Intra-Cellular Therapies overview
Intra-Cellular Therapies (ICTI) is a biopharmaceutical company that discovers and developed and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders. The compnay pipeline includes lumateperone for the treatment of the major depressive disorder and bipolar depression and TI-1284-ODT-SL for the treatment of agitation and psychosis in patients with Alzheimer’s. ICTI’s other pipeline includes PDE inhibitor for Parkinson’s and cancer immunotherapy and ITI-333 for opioid use disorder, pain and mood disorders. It also utilizes CNSProfile, a technology platform that monitors the phosphoprotein changes elicited by major psychotropic drug classes and subclasses and generates a unique molecular signature for drug compounds. ICTI is headquartered in New York, the US.
For a complete picture of ITI-333’s drug-specific PTSR and LoA scores, buy the report here.